American Ginseng Attenuates Colitis-Associated Colon Carcinogenesis in Mice: Impact on Gut Microbiota and Metabolomics

Chong-Zhi Wang1,2, Chunhao Yu1,3, Xiao-Dong Wen1,4, Lina Chen1,5, Chun-Feng Zhang1,4, Tyler Calway1,2, Yunping Qiu6, Yunwei Wang7, Zhiyu Zhang1,2, Samantha Anderson1, Yitao Wang8, Wei Jia9, and Chun-Su Yuan1,2,10

Abstract

Inflammatory bowel disease is a risk factor for colorectal cancer initiation and development. In this study, the effects of American ginseng on chemically induced colitis and colon carcinogenesis were evaluated using an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model. During the acute phase on day 15, the oral administration of ginseng (15 and 30 mg/kg/day) significantly suppressed AOM/DSS-induced colitis, as demonstrated by the disease activity index and colon tissue histology. During the chronic phase in week 13, AOM/DSS-induced tumor multiplicity was significantly suppressed by ginseng. Ginseng significantly attenuated the increase of inflammatory cytokines, such as IL1α, IL1β, IL6, G-CSF, and GM-CSF. Serum metabolomics data in the PCA plots showed good separation between the AOM/DSS model and ginseng-treated mice, and the most important endogenous metabolite changes were identified. The 16S rRNA data showed that after AOM/DSS, the microbiome community in the model group was obviously changed, and ginseng inhibited these changes. Fecal metabolomics analysis supported these findings. In conclusion, oral ginseng significantly decreased AOM/DSS-induced colitis and colon carcinogenesis by inhibiting inflammatory cytokines and restoring the metabolomics and microbiota profiles accordingly. Selective endogenous small molecules could be used as biomarkers to elucidate the effects of ginseng treatment.

Introduction

Colorectal cancer is one of the most common malignancies in the world (1, 2). Ulcerative colitis is a risk factor for colorectal cancer initiation and development (3, 4). Previous studies have provided evidence that anti-inflammatory phytochemicals possess unique modes of action against colorectal cancer (5, 6). In this regard, identifying botanical sources as an alternative strategy to develop better prevention and treatment options could be an effective step in advancing the management of colorectal cancer. American ginseng [Panax quinquefolius L. (P. quinquefolius L.)] is a very commonly used herbal medicine in the United States, and ginsenosides are considered to be its bioactive constituents (Fig. 1A and B; refs. 7–9). As an anti-inflammatory botanical, ginseng plays a therapeutic role in reducing inflammation and suppressing colitis (10, 11). Interestingly, epidemiologic and experimental studies have suggested that ginseng can prevent or treat cancer in humans, including colorectal cancer (6, 12, 13). Thus, the anti-inflammatory activity of ginseng may play a critical role in colorectal cancer chemoprevention (10, 11).

Ginseng’s bioavailability after its oral ingestion is low, due to the incomplete absorption of the parent compound and conversion to metabolites (14, 15). The ingested parent ginseng compounds can be biotransformed to metabolites by the enteric microbiome (16, 17). Although host–microbial interactions in the mammalian colon are complex and incompletely understood, they play an important role in maintaining intestinal homeostasis and protecting colorectal carcinogenesis (18). Therefore, the study of the shift of gut microbiota community induced by ginseng may provide new information on colorectal cancer management. However, the effects of ginseng compounds on gut microbial species have yet to be investigated in an in vivo colorectal cancer model.

In this study, an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model was used to evaluate the effects of American ginseng on attenuating colitis and colon carcinogenesis. A metabolomic analysis (19, 20) was conducted to detect endogenous metabolite changes for potential biomarkers. In addition, the enteric microbiota population changes induced by ginseng in the context of its treatment were also characterized using a 16S rRNA gene-based analysis.

Materials and Methods

Plant materials, extraction, and analysis

The root of P. quinquefolius L. was collected from Roland Ginseng LLC. The voucher specimen was authenticated and...
deposited at the Tang Center for Herbal Medicine Research at the University of Chicago (Chicago, Illinois). Ginseng extraction and high-performance liquid chromatography (HPLC) analysis were conducted (21, 22).

Animals and experimental protocols

The experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Chicago. Approximately 6-week-old male A/J mice, weighing between 18 and 22 g, were obtained from The Jackson Laboratory.

As shown in Fig. 1C, animals were separated into 4 groups (n = 10/group): the normal control or control group, the AOM/DSS model or model group, the American ginseng low dose (15 mg/kg/day) or American ginseng 15 group, and the high-dose (30 mg/kg/day) or American ginseng 30 group. Except for animals in the control group, all animals initially received a single intraperitoneal injection of AOM (7.5 mg/kg), and one week after the AOM injection (set as day 1), the animals began receiving 2.5% DSS in drinking water for 8 consecutive days. Animals in the model group received only AOM/DSS without any ginseng. The ginseng group animals received American ginseng extract at 110 or 220 ppm in standard AIN-76A chow from day 1 to week 13. We calculated that the daily dose of ginseng was approximately 15 and 30 mg/kg/day, respectively. In addition, for the acute phase observation, 5 animals per group were sacrificed on day 15. The remaining 5 animals were kept in the chronic phase and were sacrificed at the end of week 13. The serum and gut tissue samples of all animals were collected. The stool samples were collected during weeks -1, 2, 5, 8, and 13.

Disease activity index and histologic assessment

AOM/DSS–induced colitis was scored on the disease activity index (DAI) in the acute phase, as described previously (23). Paraffin-embedded gut tissue samples were serially sectioned, and some sections were stained with hematoxylin and eosin (H&E). The stained sections were subsequently examined for histopathologic changes by a gastrointestinal pathologist.

RNA extraction and qRT-PCR

Total RNA was isolated from the mouse colonic tissue using the miRNeasy Kit (Qiagen). First-strand cDNA was synthesized using a Maxima First Strand cDNA Synthesis Kit (Thermo Scientific). qRT-PCR was performed on a 7900HT RT-qPCR system (Applied Biosystems). The primers used for real-time PCR were described previously (24, 25). β-Actin was used as an endogenous control.

ELISA

Proteins of the mouse colonic tissue were extracted with RIPA lysis buffer (Thermo Scientific). The levels of cytokines IL1β and IL6 were quantified by ELISA (Life Technologies; ref. 24).
Metabolomic analysis using GC/TOF-MS
Serum and stool samples were pretreated with different solvents and derivatization reagents (24, 26). Gas chromatography–mass spectroscopy (GC-MS) analyses were performed on an Agilent 7890N gas chromatograph coupled with a Pegasus HT time-of-flight mass spectrometer (LECO Corporation; ref. 24). Metabolomic data were analyzed using principle component analysis (PCA). The differential metabolites were selected when they met the requirements of variable importance in the projection (VIP) >1 in the OPLS model. Compared with the control, the corresponding fold change was calculated and the most changed small molecules were identified (24).

Fecal microbiota terminal-RFLP analysis
Fecal samples were mixed and homogenized in 1 mL extraction buffer. Standard DNA extraction with phenol:chloroform:isoamyl alcohol and precipitation with ethanol was performed (27). 16S rRNA gene sequences were amplified from DNA templates using broad-range primers 8F (5'-AGAGTTTGATCCTGGCTCAG-3') labeled with 6'-carboxyfluorescein (6-FAM) and 1492R (5'-GGTACCTTGTTACGACTT-3') for the bacterial domain. Aliquots of purified PCR products were digested by Msp I (New England Biolabs) and subsequently were subjected to capillary electrophoresis using the DNA sequencer 3130 (Applied Biosystems) (26). PCA plots were generated using fluorescently labeled 5'-terminal restriction fragments (28).

Fecal 16S rRNA sequencing–based phylogenetic analysis
The 16S rRNA gene sequencing was performed by an Illumina MiSeq DNA sequencer at the Argonne National Laboratory (28). Raw sequence data were processed with the QIIME toolkit. Using the QIIME wrappers, operational taxonomic units (OTU) were picked at 97% sequence identity using cdhit, and a representative sequence was then chosen for each OTU by selecting the most abundant sequence in that OTU. The RDP classifier analysis was used to assign 16S rRNA sequences to the taxonomical hierarchy at the phylum level (29).

Statistical analysis
All data were expressed as mean ± SD. A Student t test and a one-way ANOVA were used to test the significance of the differences between ginseng treatment and model groups. The statistical significance was set at P < 0.05.

Results
Phytochemical analysis of American ginseng
The HPLC chromatogram of American ginseng extract is shown in Fig. 1A. The chemical structures of the major ginsenosides are shown in Fig. 1B. The ginsenoside content ratio of the protopanaxatriol group to the protopanaxadiol (PPD) group was 1:2.8. The contents of ginsenosides Rb1, Rc, Rd, Rg1, and Re were 28.1%, 31.2%, 30.8%, 8.6%, and 13.1%, respectively. Compound K (CK), ginsenoside Rg3, and PPD are the major metabolites transformed by the intestinal microbiota (Figs. 1B and 6; refs. 15, 17).

Ginseng attenuated AOM/DSS–induced acute colitis
After AOM/DSS administration, animals in the model group showed apparent diarrhea and rectal bleeding, starting on day 4. As the treatment continued, the presence and development of inflammation was clearly demonstrated. The disease severity, scored by DAI, reached the highest level on day 9. Fig. 2A shows the effects of American ginseng on the inflammation, which resulted in the reduction of the DAI score in a dose-related manner (P < 0.01).

Ginseng changed the serum endogenous metabolite profile in acute colitis mice
The typical GC-MS total ion current chromatograms of serum samples from the control, model, and two ginseng groups on day 15 are shown in Fig. 2D. Visual inspection of the GC-MS spectra revealed obvious differences between the four groups.

Multivariate analyses were performed to reduce the data to a low dimensional space, where discrimination of metabolomic profiles between the groups was possible. A total of 228 metabolites were annotated in the day 15 serum samples. All 20 samples from the four experimental groups were analyzed with an unsupervised PCA model. A clear separation tendency can be observed in the scores plot (2 components, R2X = 0.579) with no outliers (Fig. 2E). Using the second component, we were able to find the separation between these four groups, with the control group having the highest scores, the model group having the lowest scores, and ginseng-treated mice having scores in between these two groups in a dose-related manner.

Ginseng decreased colon carcinogenesis and chronic colitis
AOM/DSS–induced tumor multiplicity was evaluated on week 13. No tumors were detected in the control group. Tumors or adenocarcinomas were detected in model and ginseng groups (incidence = 100%). The representative macroscopic morphologic control for the model, and two ginseng groups are shown in Fig. 3A. Obvious carcinogenesis was observed in the model group. In contrast, the tumors were both fewer in number and smaller in size in both ginseng groups. The representative histologic H&E staining sections of the four groups are shown in Fig. 3B and C. Tumor multiplicity data are shown in Fig. 3C. Compared with the model group, ginseng treatment significantly and dose dependently reduced tumor numbers (P < 0.05 and P < 0.01, respectively).

The effects of American ginseng on the expression of inflammatory cytokines were examined in normal colon tissue on week 13. Real-time PCR data showed that the expression of 5 inflammatory cytokines (IL1α, IL1β, IL6, G-CSF, and GM-CSF) in the model group was significantly higher than it was in the control group (all P < 0.001). On the basis of the differences between the control group and ginseng group, it can be concluded that ginseng treatment significantly decreased the expression of these inflammatory cytokines in a dose-dependent manner (all P < 0.01; Fig.
An ELISA assay showed that compared with the model group, the levels of IL1β and IL6 in the colonic tissue were downregulated ($P < 0.05$ and $P < 0.01$; Fig. 3E), which is consistent with the real-time PCR data.

Serum endogenous metabolite profile changes

In the chronic phase, 208 metabolites were annotated in the serum samples, of which 103 metabolites were detected to be differentially expressed in the model group compared with the control group, including amino acids, lipids, and carbohydrates. Compared with the model group, the most obvious differences in metabolites in the ginseng groups are shown in Fig. 4A and B. The PCA showed a clear separation between samples from the model and control group (PC1 and PC2, 2 components, $R^2_X = 0.696$; Fig. 4C). Good separations were also obtained in the PCA plot between model mice and ginseng-treated mice, and the high-dose ginseng group was closer to that of the control group.

Effects of ginseng on intestinal microbiome populations

Fecal samples were examined by T-RFLP analysis. As shown in Fig. 5A, on week 2, remarkable differences in T-RFLP profiles were observed between the control group and the other groups. The changes in the fecal microbiota profile over time (week 1 through week 13) were analyzed using PCA of T-RFLPs. As shown in Fig. 5B, the plots of the model group are far away from those of the control group after AOM/DSS. From week 5 to week 13, the plots of the ginseng group were very close to those of the control group.

To analyze specific bacterial phylotypes, 16S rRNA gene clone libraries were established and sequenced. The majority of sequences were classified into two phyla, Firmicutes and Bacteroidetes. Among the different groups, a relatively stable composition was observed in the normal control group. However, there was a clear difference in the model group after AOM/DSS, with significantly increased levels of Bacteroidetes and Verrucomicrobia, and decreased levels of Firmicutes. In contrast, after treatment, although the proportion of Firmicutes was somewhat reduced at week 2, this level was quickly increased, while the levels of Bacteroidetes and Verrucomicrobia were decreased (Fig. 5C). This result supported our terminal-RFLP data, in which AOM/DSS significantly changed the intestinal microbiota populations. Ginseng treatment restored the gut microbiota communities to compositions resembling those of the healthy control group.
To investigate whether the metabolic variations were associated with ginseng, fecal metabolites were analyzed. A total of 493 metabolites were annotated in the week 13 fecal samples. The most obvious differences in metabolites between the model and ginseng groups are shown in Fig. 5D and E. Clear separations were obtained between samples collected from the model and ginseng groups in the PCA scores plot (2 components, $R^2_X = 0.684$), while plots of the ginseng group were close to those of the control group.

Fecal metabolite profile changes

To investigate whether the metabolic variations were associated with ginseng, fecal metabolites were analyzed. A total of 493 metabolites were annotated in the week 13 fecal samples. The most obvious differences in metabolites between the model and ginseng groups are shown in Fig. 5D and E. Clear separations were obtained between samples collected from the model and ginseng groups in the PCA scores plot (2 components, $R^2_X = 0.684$), while plots of the ginseng group were close to those of the control group.

Figure 4.
Metabolomic analysis of serum samples in week 13. A and B, top 10 metabolites responsible for the separation between the model and ginseng groups. A, top five upregulated metabolites. B, top five downregulated metabolites. EPA, 5,8,11,14,17-eicosapentaenoic acid; 5-HTP, 5-hydroxy-L-tryptophan; oleic acid, 9-octadecenoate. Ordinate values are peak area ratios, that is, relative concentrations (peak area of each group/peak area of control group) of each metabolite. C, metabolic profiling of serum samples. PCA score plot showing data from different groups. Model, AOM + DSS; AG, American ginseng; AG 15, AOM + DSS + AG (15 mg/kg/day); AG 30, AOM + DSS + AG (30 mg/kg/day). *, $P < 0.05$ and **, $P < 0.01$ compared with the model group.
Figure 5.
Microbiota and metabolomic analyses of stool samples. A–C, effects of American ginseng on the structure of intestinal microbiota. A, representative T-RFLP chromatograms from different sized bacterioplankton populations. B, T-RFLP-based PCA profiles showing differences in the microbiota profile. C, taxonomic composition of the microbiota at the phylum level identified by high-throughput 16S rRNA gene sequencing. C, control; M, model; and AG, American ginseng 30 mg/kg/day. Numbers 1, 2, 3, 4, and 5 (x-axis), weeks -1, 2, 5, 8, and 13, respectively. D–F, metabolomic analysis of samples in week 13. D and E, top 10 metabolites responsible for the separation between the model and ginseng groups. D, five downregulated metabolites: 2-HBA, 2-hydroxybutanoic acid; HCA, hydrocinnamic acid; MA, malic acid; XA, xanthurenic acid; HAA, hydroxyacetic acid. E, five upregulated metabolites: Thr, threonine; Glu, glutamate; L-Orn, L-ornithine; LA, linolenic acid; NANA, N-acetylneuraminic acid. F, metabolic profiling of stool samples. PCA score plot showing data from different groups. **, P < 0.01 compared with the model group.
(Fig. 5F). These results are consistent with the above microbiota community data.

**Discussion**

As a commonly used herbal medicine, ginseng has many reported health benefits, including cancer prevention (30). We previously observed that after oral administration, parent ginseng compounds were biotransformed by the enteric microbiome to metabolites such as Rg3, Rh1, CK, and PPD (16, 17). We have also shown that these ginseng metabolites have potential anticancer effects on colorectal cancer (31–33). In this study, we evaluated the effects of oral American ginseng on AOM/DSS–induced colitis and colorectal carcinogenesis and the subsequent changes in metabolomics and gut microbiota profiles. The ginseng was added to the rodent chow for better dose titration.

In the acute phase, chemically induced colitis was significantly reduced by ginseng in a dose-dependent manner, which was supported by histology evaluation. In the chronic phase, obvious colon carcinogenesis was observed in the model group. Ginseng treatment significantly reduced colon tumor multiplicity, consistent with proinflammatory cytokine level changes. Our results suggested that ginseng attenuated the colitis and colon carcinogenesis in part via the depression of proinflammation (Fig. 6).

Metabolomic fingerprinting is the systematic and unbiased study of small endogenous metabolites (34). In the acute colitis phase, serum metabolomic analysis showed that the plots of the model group were clearly separated from the normal control group, while ginseng treatment, especially in high-dose group, pushed the plots back toward the control group (Fig. 2E). In the chronic phase, our data suggested that in the model group, the levels of several key endogenous metabolites were significantly up- or downregulated. Compared with the model group, the levels of the most regulated metabolites were close to those of the normal control group, indicating beneficial effects of this herbal medicine. As an amino acid source, glutamine played an important role in coloocyte nutrition and integrity (35). Glutamine could inhibit colonic inflammation through the downregulation of IL8 and TNFα expressions (36). The ginseng-mediated increase in the glutamine level was likely linked to the inhibition of AOM/DSS–induced acute and chronic inflammation. Furthermore, glutamine synthetase played an essential role in the metabolism of nitrogen by catalyzing the condensation of glutamate and ammonia to form glutamine. Recently, a new mechanism of tumor growth regulation by glutamine synthetase has been reported, in which the overexpression of glutamine synthetase resulted in tumor cell growth arrest and motility suppression via activation of the expression of p21 and cyclin D1 (37). In the model group animals, since the integrity of the colon was damaged, the gut tissue glutamine level was significantly lower than that of the control. Ginseng-treated animals reversed this glutamine level reduction, suggesting ginseng's effects on inflammation and carcinogenesis. In addition, an inflammation-associated increased energy consumption was observed, including reduced levels of 6-P-glucose and 6-P-gluconic acid, and increased levels of lipids, such as EPA and oleic acid. Ginseng appears to restore the levels of observed key endogenous metabolites.

Bacteria are an important component of the human body (38). We previously observed that intestinal microbiota are critical for the conversion of ginseng metabolites (16, 17), and these metabolites showed significant antitumor potential (8, 32). In this study, we observed that the intestinal microbiome community underwent obvious changes after ginseng administration,
including increases in Firmicutes and decreases in Bacteroidales and Verrucomicrobia. It was reported that certain Gram-negative phyla (e.g., Bacteroidales and Verrucomicrobia) promote tumorigenesis, whereas certain Gram-positive phyla (e.g., Firmicutes) have anti-inflammatory and antimutagenic properties (18, 39). We observed that ginseng treatment effectively restored the enteric microbiome community to a healthy state and protected against pathologic processes (Fig. 6).

Fecal metabolomic analysis showed that the composition of fecal metabolites in the model group was different from that in the control. In ginseng group, the composition was very similar to that of the normal control. A recent report revealed that the content of several compounds, including malic acid and 3-hydroxybutanoic acid, was significantly higher in tumor tissue compared with normal tissue (40). In our study, very high concentrations of malic acid and 2-hydroxybutanoic acid were also observed in the stool samples of the model group, which may have enhanced carcinogenesis. As expected, the contents of these two compounds were decreased very significantly after ginseng administration. In addition, it was found that linolenic acid possesses antitumorigenesis potential via gut mucosa protection and proinflammatory cytokine inhibition (41). In the stool samples, AOM/DSS very significantly decreased the level of linolenic acid, while its level was restored by ginseng. Fecal metabolomic results suggested that ginseng treatment may have an ability to maintain healthy communities and functions of intestinal microbiota. In this study, we observed that American ginseng significantly attenuated AOM/DSS–induced colitis and colon carcinogenesis, which was linked to the inhibition of inflammatory cytokines. We used a platform combining metabolomic and microbiome data to interpret the efficacies of ginseng, and our data showed that along with anticancer effects, ginseng also changed the metabolic and microbiota profiles accordingly. With further verification, selective endogenous small molecules could be used as biomarkers to elucidate the effects of ginseng on colitis-associated colorectal cancer. Data from this study suggest that American ginseng compounds may have potential value in colorectal cancer chemoprevention.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: C.-Z. Wang, Z. Zhang, C.-S. Yuan
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.-Z. Wang, C. Yu, X.-D. Wen, C.-F. Zhang, Y. Qiu, Z. Zhang, Y. Wang, C.-S. Yuan
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.-Z. Wang, C. Yu, C.-F. Zhang, Y. Qiu, Z. Zhang, Y. Wang, W. Jia, C.-S. Yuan
Writing, review, and/or revision of the manuscript: C.-Z. Wang, T. Calway, Y. Qiu, Y. Wang, S. Anderson, C.-S. Yuan
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.-Z. Wang, C. Yu, L. Chen, Y. Wang, C.-S. Yuan
Study supervision: C.-S. Yuan

Grant Support
This work was supported in part by the NIH/NCCAM grants P01 AT 004418 (to C.-S. Yuan) and K01 AT005362 (to C.-Z. Wang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 23, 2015; revised June 16, 2016; accepted July 7, 2016; published OnlineFirst July 21, 2016.

References
American Ginseng Attenuates Colitis-Associated Colon Carcinogenesis in Mice: Impact on Gut Microbiota and Metabolomics

Chong-Zhi Wang, Chunhao Yu, Xiao-Dong Wen, et al.


Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-15-0372

This article cites 41 articles, 7 of which you can access for free at:
http://cancerpreventionresearch.aacrjournals.org/content/9/10/803.full#ref-list-1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, use this link http://cancerpreventionresearch.aacrjournals.org/content/9/10/803. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.